ANDA 203795, held by Jubilant Generics. Montelukast Sodium.
As of Nov 21, 2026, ANDA 203795 (Montelukast Sodium), held by Jubilant Generics, was first approved by FDA on Feb 27, 2015, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2015 | Original application | Approved | None posted |
| Montelukast SodiumEQ 4MG BASE ยท tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Montelukast SodiumEQ 5MG BASE ยท tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Nov 13, 2020 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 10Labeling ยท Standard review | Approved | None posted |
| Nov 13, 2020 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Dec 7, 2015 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Feb 27, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters